Last reviewed · How we verify
NCT03460821
Validation of a German Translation and Cultural Adaptation of the Addenbrooke's Cognitive Examination III
trial in Neurocognitive Dysfunction in 20 participants. Completed in 31 March 2018.
31 March 2018
Quick facts
| Lead sponsor | Charite University, Berlin, Germany |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 March 2018 |
| Primary completion | 31 March 2018 |
| Estimated completion | 31 March 2018 |
| Sites | 1 location across Germany |
Conditions studied
- Neurocognitive Dysfunction — all drugs for Neurocognitive Dysfunction →
Sponsor
Charite University, Berlin, Germany
Who can join
Adults 18 to 67, any sex, with Neurocognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the entire project was to perform a translation and cultural adaptation of the Addenbrooke's Cognitive Examination - III (ACE-III), adhering to the Translation and Cultural Adaptation of Patient Reported Outcomes Measures-Principles of Good Practice, in order to make it available to German clinicians. Part of the translation process is the cognitive debriefing which will be performed as a survey which rates the applicability of every single item as well as of the entire Addenbrooke's Cognitive Examination - III tool.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03460821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurocognitive Dysfunction
Currently open trials in the same condition.
- NCT06413173 — Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric) · NA · recruiting
- NCT05591924 — Early Severe Illness TrAnslational BioLogy InformaticS in Humans · recruiting
- NCT06112639 — The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders · NA · recruiting
- NCT05367245 — Ca-Mg Butyrate in GWI · Phase 2 · recruiting
- NCT05245903 — Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside · recruiting
Other Charite University, Berlin, Germany trials
Trials by the same sponsor.
- NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
- NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
- NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
- NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
- NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03460821 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
- Last refreshed: 11 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03460821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing